

Glucocorticoid Receptor Gene Bcl1 Polymorphism in Rheumatoid Arthritis

Thesis

*Submitted for Partial Fulfillment of the Master Degree
in Clinical Pathology*

By

Rania Salah Eldin Morsy Seddek

M.B.B.Ch

Faculty of Medicine, Ain Shams University

Under Supervision Of

Prof. Dr. Mona Fathy Youssef

Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Assist. Prof. Manal Mohsen M. Kamal Eldin

Assistant Professor of Clinical Pathology

Faculty of Medicine - Ain Shams University

Dr. Nashwa Aly Morshedy

Lecturer of Internal Medicine and Rheumatology

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2018



Acknowledgement

First of all, all gratitude is due to **Allah** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

Really I can hardly find the words to express my gratitude to **Prof. Dr. Mona Fathy Youssef**, Professor of Clinical Pathology, Faculty of Medicine - Ain Shams University, for her supervision, continuous help, encouragement throughout this work and tremendous effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.

I would like also to express my sincere appreciation and gratitude to **Assist. Prof. Manal Mohsen M. Kamal Eldin**, Assistant Professor of Clinical Pathology, Faculty of Medicine - Ain Shams University, for her continuous directions and support throughout the whole work.

I cannot forget the great help of **Dr. Nashwa Aly Morsheddy**, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine - Ain Shams University, for her invaluable efforts, tireless guidance and for her patience and support to get this work into light.

Words fail to express my love, respect and appreciation to **my husband** for his unlimited help and support.

Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.



Rania Salah Eldin Morsy Seddek

List of Contents

	Page
Acknowledgment	--
List of Abbreviations	i
List of Figures	iv
List of Tables	vi
Introduction	1
Aim of The Work	2
Review of Literature	3
Chapter 1 : Rheumatoid Arthritis	3
Chapter 2 : Glucocorticoid Receptor	28
Patients and Methods	44
Results	56
Discussion	70
Summary	78
Conclusion	80
Recommendations	81
References	82
Arabic Summary	--

List of Abbreviations

ACPA	: Anti-citrullinated peptide antibodies
ACR	: The American College of Rheumatology
AKA	: Antikeratin antibodies
Anti-Sa	: Anti-Savoie
APF	: Targeting pro-filaggrin
ARMS	: Amplification Refractory Mutation System
ASH	: Allele-specific oligonucleotide hybridization
ASO	: Allelic-specific oligonucleotides
bDMARDs	: biological agents
BMI	: Branch Migration Inhibition
bp	: base pair
CarP	: Anti-carbamylated protein
CBC	: Complete Blood Counts
CI	: Confidence intervals
cis-eQTL	: cis-expression quantitative trait loci
COX-2	: Cyclooxygenase type 2
CRP	: C reactive protein
csDMARDs	: Conventional sDMARDs
CSF1R	: Colony-stimulating factor 1 receptor;
CVS	: Cardiovascular system
DAS	: Disease activity score
DBD	: DNA-binding domain
ddNTP	: di-deoxynucleotide
DMARDs	: Disease modifying antirheumatic drugs
DNA	: Deoxyribonucleic acid
EBV	: Epstein-Barr virus
EDTA	: Ethylene diamine tetra acetic acid
ELISA	: Enzyme-linked immunosorbent assay
ESR	: Erythrocyte Sedimentation Rate
EULAR	: European League Against Rheumatism
FLSs	: Fibroblast-like synoviocytes
FRET	: Fluorescence resonance energy transfer
GCs	: Glucocorticoids

List of Abbreviations (Cont.)

GR	: Glucocorticoid receptor
GREs	: GCs responsive elements
GWAS	: Genome-wide association studies
HLA	: Human Leukocyte Antigen
HPA	: Hypothalamic pituitary adrenal gland
HSP	: Heat shock proteins
ICAM-1	: Intercellular adhesion molecule-1
IL-1Ra	: IL-1 receptor antagonist
IL-6	: Interleukin-6
JAKs	: Janus kinases
LAK	: Lymphokine-activated killer
LBD	: Ligand-binding domain
MBs	: Molecular beacons
M-CSF	: Macrophage colony-stimulating factor
MM	: Mismatch
MMP	: Matrix metalloproteinase;
MRI	: Magnetic resonance imaging
mRNA	: messenger Ribonucleic acid
NK	: Natural killer
NLS	: Nuclear localization sequences
NO	: Nitric oxide
NSAIDs	: Nonsteroidal anti-inflammatory drugs
NTD	: N-terminal regulatory domain
OLA	: Oligonucleotide ligation assay
OR	: Odds ratios
PAD	: Peptidylarginine deiminase
PCR	: Polymerase chain reaction
PDGFR	: Platelet-derived growth factor receptor;
PGE2	: Prostaglandin-E2
PM	: Perfect-match
PTPN	: Protein tyrosine phosphatase non-receptor 22
RA	: Rheumatoid arthritis

List of Abbreviations (Cont.)

RANKL	: Receptor activator for nuclear factor κ B ligand
RFLP	: Restriction fragment length polymorphisms
RNA	: Ribonucleic acid
SD	: Standard deviation
SNP	: Single-nucleotide polymorphism
SSCP	: Single-Strand Conformation Polymorphism
TCR	: T-cell receptor
TGF	: Transforming growth factor
TH1	: T helper 1
TLR	: Toll-like receptor
TNF	: Tumour necrosis factor
TNF	: Tumor necrosis factor
tsDMARD	: Targeted sDMARD
US	: Ultrasound
VAS	: Visual analogue scale

List of Figures

Fig.	Title	Page
1	Pathogenesis of RA.	9
2	Inflammatory process of RA.	10
3	Role of ILs in pathogenesis.	12
4	Boggy swelling in proximal interphalangeal and metacarpophalangeal joints (more prominent on patient's right hand) in a patient with new-onset rheumatoid arthritis.	13
5	Diagram demonstrating the 28 joints involved in DAS 28 score.	16
6	Schematic representation of the regulation of glucocorticoid levels by the (HPA) axis.	28
7	Glucocorticoid receptor gene chromosome location.	29
8	Structure of glucocorticoid receptor.	30
9	Structure of glucocorticoid receptor.	32
10	Mechanism of action of glucocorticoid receptor.	32
11	A point mutation (represented by a dot on a DNA strand) leads to the formation of different single-strand conformations of the mutant DNA (M) compared with the non-mutant molecule (N), resulting in differential mobilities in a non-denaturing gel matrix.	35
12	Illustration of the allelic discrimination reactions.	37

List of Figures (Cont.)

Fig.	Title	Page
13	Schematic representation of allele-specific PCR using FRET probes.	38
14	Molecular beacons.	40
15	Simplified scheme for BMI.	43
16	PCR-RFLP results of BCL1 gene polymorphisms show digested DNA product of 7 samples.	53
17	Frequency of different BCL1 genotypes in patients' group and control group.	60
18	Comparison between BCL1 genotypes and disease activity.	69

List of Tables

Table	Title	Page
1	PCR Amplification Steps.	51
2	Descriptive and Comparative Statistics of The Studied Parameters Between Patients and Control Groups Using Student's t-test and Wilcoxon Rank Sum Test.	58
3	Descriptive Statistics of Patients' Group (n=50) Regarding Clinical and Laboratory Parameters.	59
4	Descriptive and Comparative Statistics Between Different BCL1 Genotypes Distribution Among Patients' Group and Control Group Using Chi-square.	60
5	Statistical Comparison of The Frequency of Genotypes of BCL1 Gene Polymorphism in RA Patients and Controls Using Chi-square Test.	61
6	Descriptive and Comparative Statistics of Allele Frequencies of BCL1 Gene Polymorphism in RA Patients and Controls Using Chi- square Test.	61
7	Descriptive Statistics of Distribution of The Three Genotypes (CC, GG, CG) Among RA Patients Regarding Sex Using Chi- square Test.	62
8	Descriptive Statistics of Distribution of The Three Genotypes (CC, GG, CG) Among RA Patients Regarding Clinical Parameters Using Kruskal Wallis Test.	63

List of Tables (Cont.)

Table	Title	Page
9	Descriptive Statistics of Distribution of The Three Genotypes (GG, CG, CG) Among RA Patients Regarding Anti CCP, DAS28 and RF Using Chi-square Test.	64
10	Descriptive Statistics of Distribution of The Three Genotypes (CC, GG, CG) Among RA Patients Regarding Treatment Using Chi-square and Kruskal Wallis Test.	65
11	Comparative Statistics Between BCL1Gene Carriers and Non-Carriers Regarding Sex Using Chi-square Test.	65
12	Comparative Statistics Between BCL1Gene Carriers and Non-Carriers Regarding Clinical Parameters Using Wilcoxon Rank Sum Test.	66
13	Comparative Statistics Between BCL1 Gene Carriers and Non-Carriers Regarding RF, Anti CCP and DAS28 Using Chi-square Test.	67
14	Comparative Statistics Between BCL1Gene Carriers and Non-Carriers Regarding Treatment Using Chi-square and Wilcoxon Rank Sum Test.	68
15	Discreptive and Comparative Statistics Between Disease Activity and BCL1 Genotype Using Chi-square Test.	68

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease attacking mainly synovial joints leading to their destruction (*Rhen et al., 2005 and Aydeniz et al., 2011*).

One of the principal lines of the treatment of rheumatoid arthritis (RA) is glucocorticoids. The latter should bind to glucocorticoid receptors to exert their action (*Chatzikyriakidou et al., 2009 and Koper et al., 2014*).

A great variability among subjects have been reported regarding sensitivity to glucocorticoids treatment. This variability may be attributed to polymorphism of glucocorticoid receptors (*Koper et al., 2014*).

Aim of the Work

The aim of this study is to investigate glucocorticoid receptor (GR) gene Bcl1 polymorphism in rheumatoid arthritis (RA) patients and healthy control subjects.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is an autoimmune disease primarily affects the synovial joints, resulting in pain, deformity and eventual functional limitation, causing substantial morbidity and accelerated mortality (*Cush et al., 2008*).

A) Epidemiology:

RA is a common chronic disease that affects about 1% of the world population (*Saxena et al., 2017*). Prevalence of RA also varies according to geographical area and population and is more prevalent in developed countries (*Andrade et al., 2017*).

RA occurs at twice the rate in women compared with men, with a prevalence of 1.06% in women (as a percentage of the total population) compared with 0.61% in men (*Nayak and Sheth, 2017*). The lifetime risk of RA in adults is 3.6 percent (1 in 28) for women and 1.7 percent (1 in 59) for men (*Amalraj et al., 2017*). The incidence of RA increases with increasing age in most populations until about the eighth decade of life, when it declines (*Silman et al., 2009 and Saxena et al., 2017*).

B) Etiology & Risk Factors:

The underlying cause of most rheumatic diseases is unknown. However, several risk factors have been identified (*Lahiri et al., 2012*).

1) Genetic Factors:

Genetic risks for RA have been acknowledged for a number of years and genome-wide association study (meta-) analyses have identified various RA-associated genes, such as HLA-DRB1, PADI4, PTPN22, TNFAIP3, STAT4 and CCR6 (*Okada et al., 2014*).

2) Hormonal Factors:

Hormonal factors, such as estrogen, have been hypothesized to be of importance for disease development (*Wallenius et al., 2010*). A higher incidence of RA is seen among women compared to men across all ages and the highest incidence among women has been reported between 55 and 64 years of age, during the peri- or postmenopausal stage (*Humphreys et al., 2013*). Generally, estrogens, in particular 17- β estradiol (E2) and prolactin, act as enhancers at least of humoral immunity, and testosterone and progesterone as natural immunosuppressants (*Ortona et al., 2016*).

3) Environmental Factors:

a. Infections:

Clearly, no single microorganism is responsible for the development of RA. Evidence supporting a role for parvovirus B19 includes the presence of viral DNA in the synovial fluid, synovial cells, and/or synovial tissue of RA patients (*Tobon et al., 2010*). EBV RNA has been identified in B cells in synovial tissue from RA patients (*Meron et al., 2010*). Sera from RA patients contain high titres of Epstein–

Barr virus (EBV) antigens and of antibodies to latent and replicative EBV antigens (*Darborg et al., 2013*). The most suspected candidate is *Porphyromonas gingivalis*, a bacterium that causes periodontitis, which is associated with RA (*Kharlamova et al., 2016*).

b. Smoking:

The relationship between smoking and RA is strongest among people who are anticitrullinated protein/peptide antibodies (ACPA-positive), a marker of auto-immune activity (*Scott et al., 2010*). The hypothesis that tobacco smoke (and other environmental exposures to the lungs, such as silica) can lead to a mucosal immune response giving rise to ACPA production has been supported by studies using high-resolution imaging techniques of the lungs, as well as by analysis of immune cells and autoantibodies in sputum and bronchial alveolar lavage from subjects at risk of developing RA (*Willis et al., 2013 and Catrina et al., 2014*).

One of the most important findings from epidemiological and risk factor studies of RA is the interaction between the HLA shared-epitope and smoking. In a population-based case-control study, the risk of developing RF-positive RA was substantially higher in smokers carrying two copies of shared-epitope genes (RR, 15.7) than in smokers with no copies of shared-epitope genes (RR, 2.4) (*Costenbader et al., 2008*).

c. Diet:

Diet has been evaluated in several studies for its role in the management of established RA (*Hagen et al., 2009*).